190 related articles for article (PubMed ID: 18227745)
1. An open-label trial of venlafaxine in body dysmorphic disorder.
Allen A; Hadley SJ; Kaplan A; Simeon D; Friedberg J; Priday L; Baker BR; Greenberg JL; Hollander E
CNS Spectr; 2008 Feb; 13(2):138-44. PubMed ID: 18227745
[TBL] [Abstract][Full Text] [Related]
2. An open-label study of citalopram in body dysmorphic disorder.
Phillips KA; Najjar F
J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
[TBL] [Abstract][Full Text] [Related]
3. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
Denys D; van der Wee N; van Megen HJ; Westenberg HG
J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
Albert U; Aguglia E; Maina G; Bogetto F
J Clin Psychiatry; 2002 Nov; 63(11):1004-9. PubMed ID: 12444814
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder.
Schneier FR; Feusner J; Wheaton MG; Gomez GJ; Cornejo G; Naraindas AM; Hellerstein DJ
J Psychiatr Res; 2023 May; 161():364-370. PubMed ID: 37004409
[TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
Phillips KA; Albertini RS; Rasmussen SA
Arch Gen Psychiatry; 2002 Apr; 59(4):381-8. PubMed ID: 11926939
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
Phillips KA; Dwight MM; McElroy SL
J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
[TBL] [Abstract][Full Text] [Related]
8. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
9. Venlafaxine in treatment-resistant obsessive-compulsive disorder.
Hollander E; Friedberg J; Wasserman S; Allen A; Birnbaum M; Koran LM
J Clin Psychiatry; 2003 May; 64(5):546-50. PubMed ID: 12755657
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.
Denys D; Van Nieuwerburgh F; Deforce D; Westenberg HG
J Clin Psychiatry; 2007 May; 68(5):747-53. PubMed ID: 17503984
[TBL] [Abstract][Full Text] [Related]
11. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
[TBL] [Abstract][Full Text] [Related]
12. The role of venlafaxine in the treatment of obsessive-compulsive disorder.
Phelps NJ; Cates ME
Ann Pharmacother; 2005 Jan; 39(1):136-40. PubMed ID: 15585743
[TBL] [Abstract][Full Text] [Related]
13. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.
Davidson J; Baldwin D; Stein DJ; Kuper E; Benattia I; Ahmed S; Pedersen R; Musgnung J
Arch Gen Psychiatry; 2006 Oct; 63(10):1158-65. PubMed ID: 17015818
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
Kaplan EM
Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
[TBL] [Abstract][Full Text] [Related]
15. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
Joffe H; Guthrie KA; LaCroix AZ; Reed SD; Ensrud KE; Manson JE; Newton KM; Freeman EW; Anderson GL; Larson JC; Hunt J; Shifren J; Rexrode KM; Caan B; Sternfeld B; Carpenter JS; Cohen L
JAMA Intern Med; 2014 Jul; 174(7):1058-66. PubMed ID: 24861828
[TBL] [Abstract][Full Text] [Related]
16. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.
Hollander E; Allen A; Kwon J; Aronowitz B; Schmeidler J; Wong C; Simeon D
Arch Gen Psychiatry; 1999 Nov; 56(11):1033-9. PubMed ID: 10565503
[TBL] [Abstract][Full Text] [Related]
17. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
Mallick R; Chen J; Entsuah AR; Schatzberg AF
J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine treatment of obsessive-compulsive disorder: case reports.
Marazziti D
CNS Spectr; 2003 Jun; 8(6):421-2. PubMed ID: 12858131
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Venlafaxine in Selective Serotonin Reuptake Inhibitor-Resistant Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
Balachander S; Kodancha PG; Arumugham SS; Sekharan JT; Narayanaswamy JC; Reddy YCJ
J Clin Psychopharmacol; 2019; 39(1):82-85. PubMed ID: 30516575
[TBL] [Abstract][Full Text] [Related]
20. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release.
Ferguson JM; Khan A; Mangano R; Entsuah R; Tzanis E
J Clin Psychiatry; 2007 Jan; 68(1):58-68. PubMed ID: 17284131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
